Treatment updates on tenosynovial giant cell tumor

In conclusion, D-TGCT impairs patients’ QoL. The evidence that the pathogenetic loop of D-TGCT can be inhibited has changed the therapeutic armamentarium for this condition. Clinical trials of agents that target CSF1R are currently ongoing. All this new evidence should be taken into consideration within multidisciplinary management.
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: SARCOMAS: Edited by Jean-Yves Blay Source Type: research